DURECT Corporation: Business Overview, Financials & Competitive Analysis
DURECT Corporation scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage epigenetic therapy platform with promising lead candidate but challenged by minimal revenue and dependency on Phase 3 trial success for strategic value. The company achieved debt-free status and reduced R&D expenses significantly from $29.4M to $10.4M, but 2024 revenue declined to $2M from $2.6M. Analyst price targets were decreased.
What is DURECT Corporation's industry? DURECT Corporation (durect.com) operates in Pharmaceuticals. AskCyborg classifies DURECT Corporation under Pharmaceuticals in its company registry.
DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acut...
Cyborg Score thesis
Early-stage epigenetic therapy platform with promising lead candidate but challenged by minimal revenue and dependency on Phase 3...
Read the full analyst-debate transcript →Get the Latest DURECT Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDURECT Corporation Overview
Pro stress-test →DURECT Corporation is a late-stage biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated DNA methylation to treat serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol, is in clinical development for alcoholic hepatitis (AH) with FDA Fast Track and Breakthrough Therapy designations, and is also being explored for metabolic dysfunction-associated steatohepatitis (MASH).
Strategic Profile
Pro stress-test →The company has a commercial pharmaceutical product, POSIMIR (bupivacaine solution), a non-opioid analgesic utilizing the SABER platform technology. As of September 2025, DURECT operates as a subsidiary of Bausch Health Americas with $12M in cash reserves and has shifted focus to advancing Larsucosterol with a Phase 3 trial estimated at $20M.
Competitive Landscape
Pro stress-test →DURECT's Larsucosterol targets epigenetic dysregulation in alcoholic hepatitis and MASH, competing in the growing liver disease therapeutic space against companies developing anti-fibrotic and metabolic therapies. The company faces competition from larger pharma and biotech firms with more substantial clinical pipelines and financial resources for Phase 3 trials.
Industry Context
DURECT Corporation operates in Pharmaceuticals.
Key facts
Founded: 1998 · Headquarters: Cupertino, California · Revenue: $2M (2024) · Market cap: N/A